Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flexion Therapeutics Inc. FLXN

Healthcare Drug Manufacturers - Major
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra... see more

Recent & Breaking News (NDAQ:FLXN)

Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018

GlobeNewswire October 31, 2018

Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting

GlobeNewswire October 22, 2018

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 5, 2018

Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology

GlobeNewswire September 10, 2018

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 7, 2018

Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference

GlobeNewswire August 28, 2018

Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium

GlobeNewswire August 20, 2018

Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel — Future Expectations, Projections Moving into 2018

GlobeNewswire August 17, 2018

Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights

GlobeNewswire August 7, 2018

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2018

Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018

GlobeNewswire July 30, 2018

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 3, 2018

Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row

GlobeNewswire June 21, 2018

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

PR Newswire Europe Non Regulatory June 13, 2018

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2018

Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights

GlobeNewswire May 8, 2018

Flexion Therapeutics Names David Arkowitz as Chief Financial Officer

GlobeNewswire May 7, 2018

Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS

GlobeNewswire May 4, 2018

Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2018

Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018

GlobeNewswire April 30, 2018